The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Plasma-Based Circulating MicroRNA Biomarkers for Parkinson's Disease
Open accessAbstract
BACKGROUND: The current "gold-standard" for Parkinson's disease (PD) diagnosis is based primarily on subjective clinical rating scales related with motor features. Molecular biomarkers that are objective and quantifiable remain attractive as clinical tools to detect PD prior to its motor onsets. OBJECTIVE: Here, we aimed to identify, develop, and validate plasma-based circulating microRNA (miRNAs) as biomarkers for PD. METHODS: Global miRNA expressions were acquired from a discovery set of 32 PD/32 controls using microarrays. k-Top Scoring Pairs (k-TSP) algorithm and significance analysis of microarrays (SAM) were applied to obtain comprehensive panels of PD-predictive biomarkers. TaqMan miRNA-specific real-time PCR assays were performed to validate the microarray data and to evaluate the biomarker performance using a new replication set of 42 PD/30 controls. Data was analyzed in a paired PD-control fashion. The validation set was composed of 30 PD, 5 progressive supranuclear palsy, and 4 multiple system atrophy samples from a new clinical site. RESULTS: We identified 9 pairs of PD-predictive classifiers using k-TSP analysis and 13 most differentially-expressed miRNAs by SAM. A combination of both data sets produced a panel of PD-predictive biomarkers: k-TSP1 (miR-1826/miR-450b-3p), miR-626, and miR-505, and achieved the highest predictive power of 91% sensitivity, 100% specificity, 100% positive predicted value, and 88% negative predicted value in the replication set. However, low predictive values were shown in the validation set. CONCLUSIONS: This proof-of-concept study demonstrates the feasibility of using plasma-based circulating miRNAs as biomarkers for neurodegenerative disorders such as PD and shows the challenges of molecular biomarker research using samples from multiple clinical sites.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Direct multiplexed measurement of gene expression with color-coded probe pairs
Geiss, G. K., Bumgarner, R. E., Birditt, B., Dahl, T., Dowidar, N., Dunaway, D. L., Fell, H. P., Ferree, S., George, R. D., Grogan, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1385 · Cited by 2,066
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048 · cited 1×
“Global proteomic studies using blood serum or plasma as a source of biomarker discoveries have been reported in Alzheimer’s disease [8–10] and, most recently, in PD with cognitive impairment [11].”
BackgroundGene regulation by transcription factors and microRNAs
Hobert, O. (2008) · Science · doi:10.1126/science.1151651 · Cited by 913
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615
Self-citationCerebellar neurodegeneration in the absence of microRNAs
Schaefer, A., O'Carroll, D., Tan, C. L., Hillman, D., Sugimori, M., Llinas, R., & Greengard, P. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070823 · Cited by 498
A Pilot Study of Circulating miRNAs as Potential Biomarkers of Early Stage Breast Cancer
Zhao, H., Shen, J., Medico, L., Wang, D., Ambrosone, C. B., & Liu, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013735 · Cited by 398 · cited 1×
“Its unique characteristics have made it feasible to develop as plasma-based biomarkers for diseases such as Huntington’s disease, myelodysplastic syndrome, myocardial infarction, and various cancers [16–23].”
BackgroundIdentification of blood microRNAs associated to Parkinsońs disease
Margis, R., Margis, R., & Rieder, C. R. M. (2011) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2011.01.023 · Cited by 263
Cited by
Burgos, K., Malenica, I., Metpally, R., Courtright, A., Rakela, B., Beach, T., Shill, H., Adler, C., Sabbagh, M., Villa, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094839 · Cited by 385
Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers
Hamam, R., Hamam, D., Alsaleh, K. A., Kassem, M., Zaher, W., Alfayez, M., Aldahmash, A., & Alajez, N. M. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.440 · Cited by 322
The Concept of Prodromal Parkinson’s Disease
Mahlknecht, P., Seppi, K., & Poewe, W. (2015) · Journal of Parkinson's Disease · doi:10.3233/jpd-150685 · Cited by 288
Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders
van den Berg, M. M. J., Krauskopf, J., Ramaekers, J. G., Kleinjans, J. C. S., Prickaerts, J., & Briedé, J. J. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101732 · Cited by 253
Circulating miRNAs as Biomarkers for Neurodegenerative Disorders
Grasso, M., Piscopo, P., Confaloni, A., & Denti, M. (2014) · Molecules · doi:10.3390/molecules19056891 · Cited by 208
Neuronal dark matter: the emerging role of microRNAs in neurodegeneration
Goodall, E. F., Heath, P. R., Bandmann, O., Kirby, J., & Shaw, P. J. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00178 · Cited by 187
Identification of a panel of five serum miRNAs as a biomarker for Parkinson's disease
Ding, H., Huang, Z., Chen, M., Wang, C., Chen, X., Chen, J., & Zhang, J. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.11.014 · Cited by 172
microRNA Profiles in Parkinson's Disease Prefrontal Cortex
Hoss, A. G., Labadorf, A., Beach, T. G., Latourelle, J. C., & Myers, R. H. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00036 · Cited by 168
microRNAs as neuroregulators, biomarkers and therapeutic agents in neurodegenerative diseases
Basak, I., Patil, K. S., Alves, G., Larsen, J. P., & Møller, S. G. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2093-x · Cited by 107
Epigenetic influence of environmentally neurotoxic metals
Ijomone, O. M., Ijomone, O. K., Iroegbu, J. D., Ifenatuoha, C. W., Olung, N. F., & Aschner, M. (2020) · NeuroToxicology · doi:10.1016/j.neuro.2020.08.005 · Cited by 99
Li, N., Pan, X., Zhang, J., Ma, A., Yang, S., Ma, J., & Xie, A. (2017) · Neurological Sciences · doi:10.1007/s10072-017-2841-9 · Cited by 97
Biomarkers in Neurodegenerative Diseases
Jeromin, A., & Bowser, R. (2017) · Advances in Neurobiology · doi:10.1007/978-3-319-57193-5_20 · Cited by 92
Identification of aberrant circulating mi RNA s in Parkinson's disease plasma samples
Chen, L., Yang, J., Lü, J., Cao, S., Zhao, Q., & Yu, Z. (2018) · Brain and Behavior · doi:10.1002/brb3.941 · Cited by 96
“…related miRNAs (being selected according to the literature) (Asikainen et al., 2010; Cardo et al., 2013; Filatova et al., 2012; Junn et al., 2009; Khoo et al., 2012; Mouradian, 2012; Salta & De Strooper, 2012; Serafin et al., 2014; Shioya et al., 2010; Wang et al., 2008), two reference small…”
BackgroundParkinson's disease: SNCA-, PARK2-, and LRRK2- targeting microRNAs elevated in cingulate gyrus
Tatura, R., Kraus, T., Giese, A., Arzberger, T., Buchholz, M., Höglinger, G., & Müller, U. (2016) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2016.09.028 · Cited by 81
MiRNA Profile in the Substantia Nigra of Parkinson’s Disease and Healthy Subjects
Cardo, L. F., Coto, E., Ribacoba, R., Menéndez, M., Moris, G., Suárez, E., & Alvarez, V. (2014) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0428-y · Cited by 75
The regulation of exosome function in the CNS: implications for neurodegeneration
Properzi, F., Ferroni, E., Poleggi, A., & Vinci, R. (2015) · Swiss Medical Weekly · doi:10.4414/smw.2015.14204 · Cited by 62
Valera, E., Spencer, B., Mott, J., Trejo, M., Adame, A., Mante, M., Rockenstein, E., Troncoso, J. C., Beach, T. G., Masliah, E., et al. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00329 · Cited by 55
“For example, up-regulation of specific miRNAs has been found in AD (Banzhaf-Strathmann et al., 2014; Tan et al., 2014), PD (Khoo et al., 2012; Vallelunga et al., 2014), frontotemporal dementia (Gascon and Gao, 2014), and MSA (Ubhi et al., 2014; Vallelunga et al., 2014), among others.”
BackgroundRavanidis, S., Bougea, A., Papagiannakis, N., Maniati, M., Koros, C., Simitsi, A., Bozi, M., Pachi, I., Stamelou, M., Paraskevas, G. P., et al. (2020) · Movement Disorders · doi:10.1002/mds.27928 · Cited by 51
The role of microRNA-485 in neurodegenerative diseases
Ryu, I. S., Kim, D. H., Cho, H.-J., & Ryu, J.-H. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0039 · Cited by 25
Metadata
- Authors
- Khoo, S. K., Petillo, D., Kang, U. J., Resau, J. H., Berryhill, B., Linder, J., Forsgren, L., Neuman, L. A., & Tan, A. C.
- Venue
- Journal of Parkinson's Disease
- Publisher
- SAGE Publications
- Published
- 2012
- Volume
- 2
- Issue
- 4
- Pages
- 321-331
- ISSN
- 1877-7171 (ISSN-L)
- 1877-718X
- OpenAlex
- W1515659971
- Cited by
- 194
- References
- 9
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.